Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
CONCLUSIONS: Beliefs about medications were a major determinant of medication non-adherence. Patient education may help alleviate the negative impact of misinformation/unawareness on adherence.PMID:38545763 | DOI:10.1177/09612033241242692 (Source: Lupus)
Source: Lupus - March 28, 2024 Category: Rheumatology Authors: Sharzad Emamikia Alvaro Gomez Theodor Ådahl Gunilla von Perner Yvonne Enman Katerina Chatzidionysiou Elizabeth V Arkema Ioannis Parodis Source Type: research
Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
CONCLUSIONS: Beliefs about medications were a major determinant of medication non-adherence. Patient education may help alleviate the negative impact of misinformation/unawareness on adherence.PMID:38545763 | DOI:10.1177/09612033241242692 (Source: Lupus)
Source: Lupus - March 28, 2024 Category: Rheumatology Authors: Sharzad Emamikia Alvaro Gomez Theodor Ådahl Gunilla von Perner Yvonne Enman Katerina Chatzidionysiou Elizabeth V Arkema Ioannis Parodis Source Type: research
Comparison of systemic lupus international collaborating clinics 2012 classification criteria and European league against rheumatism/American college of rheumatology 2019 classification criteria for early detection of childhood onset systemic lupus erythematosus (multi-center study)
CONCLUSION: In this cohort among the Saudi population with childhood-onset SLE, the new EULAR/ACR 2019 criteria efficiently enable early detection of SLE, although a more frequent rate of false positives was observed with them. Escalating the total score from ≥ 10 to ≥ 13 in the cSLE population improved the specificity close to that of SLICC 2012. Further prospective studies in pediatrics need to be done for the validation of a cut- off score of ≥ 13 in cSLE rather than the traditional score of ≥ 10 in aSLE.PMID:38533912 | DOI:10.1177/09612033241240830 (Source: Lupus)
Source: Lupus - March 27, 2024 Category: Rheumatology Authors: Esraa Babgi Munira Al Marri Sulaiman M Al-Mayouf Rawia Shehata Mahmoud Majeed Khayriah Alsufyani Entesar Batouk Reema Bakri Ashwaq AlE'ed Mada Yateem Lujayn Akbar Shahad Gari Wafa Alghamdi Abdularahman Asiri Abdulaziz Al Rowais Source Type: research
The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study
CONCLUSION: Belimumab shows promising clinical outcomes in the treatment on patients with both SLE and ITP. Further studies are needed to validate these findings in larger patient populations and compare the efficacy of belimumab with other treatments for SLE complicated with ITP. Long-term response rates and adverse events associated with belimumab treatment also warrant further investigation.PMID:38518059 | DOI:10.1177/09612033241241576 (Source: Lupus)
Source: Lupus - March 22, 2024 Category: Rheumatology Authors: Qi Wu Ming-Xue Zhao Xiao-Shan Huang Chang-Song Lin Qiang Xu Source Type: research
The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study
CONCLUSION: Belimumab shows promising clinical outcomes in the treatment on patients with both SLE and ITP. Further studies are needed to validate these findings in larger patient populations and compare the efficacy of belimumab with other treatments for SLE complicated with ITP. Long-term response rates and adverse events associated with belimumab treatment also warrant further investigation.PMID:38518059 | DOI:10.1177/09612033241241576 (Source: Lupus)
Source: Lupus - March 22, 2024 Category: Rheumatology Authors: Qi Wu Ming-Xue Zhao Xiao-Shan Huang Chang-Song Lin Qiang Xu Source Type: research
The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study
CONCLUSION: Belimumab shows promising clinical outcomes in the treatment on patients with both SLE and ITP. Further studies are needed to validate these findings in larger patient populations and compare the efficacy of belimumab with other treatments for SLE complicated with ITP. Long-term response rates and adverse events associated with belimumab treatment also warrant further investigation.PMID:38518059 | DOI:10.1177/09612033241241576 (Source: Lupus)
Source: Lupus - March 22, 2024 Category: Rheumatology Authors: Qi Wu Ming-Xue Zhao Xiao-Shan Huang Chang-Song Lin Qiang Xu Source Type: research
The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study
CONCLUSION: Belimumab shows promising clinical outcomes in the treatment on patients with both SLE and ITP. Further studies are needed to validate these findings in larger patient populations and compare the efficacy of belimumab with other treatments for SLE complicated with ITP. Long-term response rates and adverse events associated with belimumab treatment also warrant further investigation.PMID:38518059 | DOI:10.1177/09612033241241576 (Source: Lupus)
Source: Lupus - March 22, 2024 Category: Rheumatology Authors: Qi Wu Ming-Xue Zhao Xiao-Shan Huang Chang-Song Lin Qiang Xu Source Type: research
Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study
CONCLUSIONS: Our study showed that a delay in belimumab initiation led to higher SLEDAI-2K score and difficulty in achieving a 50% GC reduction at 96 weeks. Since GC-related adverse events increase with long-term administration of GC though with small daily doses, we proposed here that belimumab should be started in combination with higher daily prednisolone.PMID:38509864 | DOI:10.1177/09612033241240859 (Source: Lupus)
Source: Lupus - March 21, 2024 Category: Rheumatology Authors: Takashi Yamane Akira Hashiramoto Source Type: research
Significant heightened methylation levels of < em > RUNX3 < /em > gene promoter in patients with systemic lupus erythematosus
CONCLUSION: The findings of this study emphasize the potential use of RUNX3 methylation levels in PBMCs of SLE patients as biomarkers for diagnosing the disease, predicting renal damage, and assessing disease activity.PMID:38511579 | DOI:10.1177/09612033241241850 (Source: Lupus)
Source: Lupus - March 21, 2024 Category: Rheumatology Authors: Naeim Ehtesham Samira Alesaeidi Dorita Mohammad Zadeh Mozhdeh Saghaei Maryam Fakhri Zahra Bayati Emran Esmaeilzadeh Meysam Mosallaei Source Type: research
Epidemiological, immunological, and treatment response profile of patients with lupus nephritis in Brazil
CONCLUSION: Late biopsy seems to be associated with negative renal outcomes in LN. However, it seems that a higher chronicity index is the main predictor of a poor renal outcome among patients with LN in Brazil.PMID:38514381 | DOI:10.1177/09612033241240869 (Source: Lupus)
Source: Lupus - March 21, 2024 Category: Rheumatology Authors: Mariana Sousa Teixeira Nunes Lect ícia Barbosa Jorge Luis Yu Viktoria Woronik Cristiane Bitencourt Dias Source Type: research
Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study
CONCLUSIONS: Our study showed that a delay in belimumab initiation led to higher SLEDAI-2K score and difficulty in achieving a 50% GC reduction at 96 weeks. Since GC-related adverse events increase with long-term administration of GC though with small daily doses, we proposed here that belimumab should be started in combination with higher daily prednisolone.PMID:38509864 | DOI:10.1177/09612033241240859 (Source: Lupus)
Source: Lupus - March 21, 2024 Category: Rheumatology Authors: Takashi Yamane Akira Hashiramoto Source Type: research
Significant heightened methylation levels of < em > RUNX3 < /em > gene promoter in patients with systemic lupus erythematosus
CONCLUSION: The findings of this study emphasize the potential use of RUNX3 methylation levels in PBMCs of SLE patients as biomarkers for diagnosing the disease, predicting renal damage, and assessing disease activity.PMID:38511579 | DOI:10.1177/09612033241241850 (Source: Lupus)
Source: Lupus - March 21, 2024 Category: Rheumatology Authors: Naeim Ehtesham Samira Alesaeidi Dorita Mohammad Zadeh Mozhdeh Saghaei Maryam Fakhri Zahra Bayati Emran Esmaeilzadeh Meysam Mosallaei Source Type: research
Epidemiological, immunological, and treatment response profile of patients with lupus nephritis in Brazil
CONCLUSION: Late biopsy seems to be associated with negative renal outcomes in LN. However, it seems that a higher chronicity index is the main predictor of a poor renal outcome among patients with LN in Brazil.PMID:38514381 | DOI:10.1177/09612033241240869 (Source: Lupus)
Source: Lupus - March 21, 2024 Category: Rheumatology Authors: Mariana Sousa Teixeira Nunes Lect ícia Barbosa Jorge Luis Yu Viktoria Woronik Cristiane Bitencourt Dias Source Type: research
ANCA in patients with systemic lupus erythematosus. A cross sectional study in Brazilian patients and review of literature
CONCLUSIONS: The ANCA prevalence found in this Brazilian sample was within the range reported in the literature and these autoantibodies were more frequent in males and in patients with vasculitis. The literature showed controversial results on the association between ANCA and SLE disease activity or clinical characteristics.PMID:38506239 | DOI:10.1177/09612033241240588 (Source: Lupus)
Source: Lupus - March 20, 2024 Category: Rheumatology Authors: Renato Nisihara Gabriela Vithoft Isabela Alencar Thiago Alberto F G Dos Santos Thelma Larocca Skare Source Type: research
Aberrant phenotypes of circulating γδ-T cells may be involved in the onset of systemic lupus erythematosus
CONCLUSION: A broad range of anomalies in the proportions of γδ-T-cell subsets and γδ-T cells in SLE patients may be involved in the pathogenesis of SLE. There is a strong association between Vδ2+ T cells and their Vδ2+NKp30+ T-cell subpopulation and LN occurrence. Our results indicate that γδ-T cells and their subpopulations might be key players in disease immunopathology and renal involvement in SLE.PMID:38506324 | DOI:10.1177/09612033241240864 (Source: Lupus)
Source: Lupus - March 20, 2024 Category: Rheumatology Authors: Shiwen Yuan Cuicui Wang Yanting Zeng Jiawei Li Weinian Li Zhixiang He Jinghua Ye Fangfei Li Yi Chen Xiaojun Lin Yan Xu Na Yu Xiaoyan Cai Source Type: research
